Lv31
340 积分 2024-05-08 加入
Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study
1小时前
已完结
Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
28天前
已完结
Measurable residual disease in hematologic malignancies: a biomarker in search of a standard
28天前
已完结
Minimal residual disease and imaging‐guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma
28天前
已完结
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
28天前
已完结
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management
28天前
已完结
The role of maintenance therapy and its cessation in patients with multiple myeloma
28天前
已完结
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
28天前
已完结
Pre‐treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma
1个月前
已完结
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma
1个月前
已完结
皖公网安备34019202002308
